Adverse events include mild [[hypoglycemia]] based on clinical studies.<ref name=seino2011/><ref name=kutoh2012/><ref name=bosi2011/> It may cause severe joint pain.<ref>{{cite web|title=DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm|website=FDA|accessdate=1 September 2015|date=2015-08-28}}</ref>

 


 
Alogliptin is not associated with increased weight, increased risk of cardiovasular events.<ref>{{cite journal |vauthors=White WB, Cannon CP, Heller SR |title=Alogliptin after acute coronary syndrome in patients with type 2 diabetes |journal=N. Engl. J. Med. |volume=369 |issue=14 |pages=1327â€“35 |date=October 2013  |pmid=23992602 |doi=10.1056/NEJMoa1305889 |url=|display-authors=etal}}</ref><ref>{{cite journal |vauthors=White WB, Zannad F |title=Saxagliptin, alogliptin, and cardiovascular outcomes |journal=N. Engl. J. Med. |volume=370 |issue=5 |pages=484 |date=January 2014  |pmid=24482824 |doi=10.1056/NEJMc1313880 |url=}}</ref> In April 2016, the U.S. FDA added a warning about increased risk of [[heart failure]].<ref name=FDA2016/>

 

